Skip to main content

Table 1 Methylation status and two-year survival of patients following surgery.

From: Qualitative analysis of Adenomatous Polyposis Coli promoter: Hypermethylation, engagement and effects on survival of patients with esophageal cancer in a high risk region of the world, a potential molecular marker

Tumor differentiation status *

Total

Survival rate

Methylated tumors

Survival rate

Unmethylated tumors

Survival rate

Poor

32

24

13 (40.6%)

8 (61%)

19 (59%)

16 (84%)

Moderate

5

4

2 (40%)

2 (40%)

3 (60%)

2 (67%)

well

8

4

5 (62%)

1 (20%)

3 (37.5%)

3 (100%)

Total

45

32

20 (44%)

11 (55%)

25 (56%)

21 (84%)

  1. *Differentiation classification according to the WHO criteria (World Health Organization, 1977)